Luminor Medical Announces Listing on the Canadian Securities Exchange
Toronto, Ontario--(Newsfile Corp. - November 30, 2017) - Luminor Medical Technologies Inc. (the "Company") (CSE: LMT) (TSXV: LMT) announced today that the Canadian Securities Exchange (CSE) has approved the Company's application to list its common shares on the CSE. Effective December 1, 2017, the Company's shares will commence trading on the CSE under the symbol LMT. The Company has also applied for a voluntary delisting of its common shares from the TSX Venture Exchange ("TSXV"). The...
2017-11-30 4:30 PM EST
Luminor Medical Acquires Jamaica-Blu Ltd. and Completes Private Placement
Montreal, Quebec--(Newsfile Corp. - September 28, 2017) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company") announces that further to its news release dated September 12, 2017, the Company has closed its acquisition of Jamaica-Blu Ltd. ("J-BLU"). J-BLU holds the exclusive Canadian licence of all current and future cannabis commercial products developed by Rise Research Inc. ("RISE"). RISE's cannabis commercial products are based on a patent pending formula, currently filed with...
2017-09-28 11:16 AM EDT
Luminor Medical Amends Terms of Jamaica BLU Acquisition and Announces Private Placement Financing
Montreal, Quebec--(Newsfile Corp. - September 12, 2017) - Luminor Medical Technologies Inc. (TSXV: LMT) ("Luminor Medical") is pleased to announce that it has amended the terms of its acquisition of Jamaica-BLU Ltd. ("J-BLU") which was previously announced on May 10, 2017 and that it plans to close up to $3,000,000 in a private placement financing (the "Financing") at a price of $0.15 per unit (a "Unit") with each Unit consisting of one common share and one half of one...
2017-09-12 9:17 AM EDT
IIROC Trade Resumption - Luminor Medical Technologies Inc.
Vancouver, British Columbia--(Newsfile Corp. - May 10, 2017) - Trading resumes in: Company: Luminor Medical Technologies Inc.
2017-05-10 11:37 AM EDT
Luminor Medical to Acquire the Exclusive Canadian Licence for Jamaica BLU Ltd.'s Cannabis Medical and Consumer Products
Montreal, Quebec--(Newsfile Corp. - May 10, 2017) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor Medical") (formerly Miraculins Inc.) is pleased to announce that it has executed a letter of intent (the "LOI") to acquire the exclusive Canadian and Jamaican licences for all current and future cannabis commercial products (the "Acquisition") owned by Jamaica BLU Ltd. ("J-BLU"). J-BLU's cannabis commercial products are based on a patent pending process to create...
2017-05-10 11:28 AM EDT
IIROC Trade Halt - Luminor Medical Technologies Inc.
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2017) - The following issues have been halted by IIROC: Company:
2017-05-08 8:46 AM EDT
Luminor Medical Announces Dr. Edward Hillhouse as Chair of its International Scientific Advisory Board and Retains Trapeze Capital Corp. for Market Making Services
Montreal, Quebec--(Newsfile Corp. - May 2, 2017) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor Medical") (formerly Miraculins Inc.), announces today that it has appointed Dr. Edward Hillhouse as Chairman of the Luminor Medical Scientific Advisory Board. Dr. Hillhouse will form an Advisory Board of International Key Opinion Leaders who value Scout DS® and share our aspiration. The role of the Advisory Board will be to provide Luminor Medical with objective,...
2017-05-02 8:55 AM EDT
Luminor Medical Announces Change in Auditor
Montreal, Quebec--(Newsfile Corp. - March 17, 2017) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor Medical") (formerly Miraculins Inc.) announces that it has changed its auditors from KPMG LLP. (the "Former Auditors") to MNP LLP. (the "Successor Auditors") effective March 10, 2017.At the request of the Company, the Former Auditors resigned as auditors of the Company effective March 10, 2017 and the board of directors of the Company appointed the Successor Auditor...
2017-03-17 5:00 PM EDT
Luminor Medical Announces Appointment of Daniel Cloutier to its Board of Directors and Grant of Stock Options
Montreal, Quebec--(Newsfile Corp. - January 20, 2017) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor Medical") (formerly Miraculins Inc.) announces the appointment of Daniel Cloutier to its Board of Directors. Daniel Cloutier is the CEO of LOK Corporation International Ltd. (www.lok-corporation.com). Supported by twelve offices worldwide, LOK Corporation specializes in consultancy services to medical device manufacturers through its two divisions LOK Network and...
2017-01-20 8:00 AM EST
Luminor Medical Completes Private Placement
Montreal, Quebec--(Newsfile Corp. - January 10, 2017) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company") (formerly Miraculins Inc.) announces that further to its news release dated December 28, 2016, the Company has closed its previously announced non-brokered private placement through the issuance of 5,050,609 units ("Units") at a price of $0.225 per Unit for gross proceeds of $1,136,387.53 (the "Offering"). Each Unit is comprised of one common share ("Common Share") of the...
2017-01-10 10:29 AM EST
Luminor Medical Technologies Inc. Announces Private Placement
Montreal, Quebec--(Newsfile Corp. - December 28, 2016) - Luminor Medical Technologies Inc. (TSXV: LMT) (formerly Miraculins Inc.) ("Luminor" or the "Company"), is pleased to announce that the Company proposes to complete a non-brokered private placement (the "Offering") of up to 9,000,000 units (the "Units") at a price of $0.225 per Unit for gross proceeds of up to $2,025,000. Each Unit will consist of one common share of the Company (a "Common Share") and a one-half Common Share purchase...
2016-12-28 4:05 PM EST
Luminor Medical Announces Closing of Equity Financing, Convertible Debt Financing and Shares for Debt Transaction
Montreal, Quebec--(Newsfile Corp. - October 24, 2016) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor Medical") (formerly Miraculins Inc.) announces it has closed the financing previously announced on September 2, 2016. Through a non-brokered private placement (the "Private Placement"), the Company has issued 2,045,000 units (each a "Unit") at a price of $0.15 per Unit for gross proceeds of $306,750. Each Unit consists of one common share and one half of one common...
2016-10-24 9:30 AM EDT
Luminor Medical Announces Equity Financing, Convertible Debt Financing and Shares for Debt Transaction
Montreal, Quebec--(Newsfile Corp. - September 2, 2016) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor Medical") (formerly Miraculins Inc.) announces it plans to complete a non-brokered financing of up to 4,000,000 units (each a "Unit") at a price of $0.15 per Unit to raise gross proceeds of up to $600,000. Each Unit will consist of one common share and one half of one common share purchase warrant (a "Warrant") with each Warrant exercisable at a price of...
2016-09-02 2:30 PM EDT
Luminor Medical Provides Corporate Update
Montreal, Quebec--(Newsfile Corp. - June 22, 2016) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor Medical") (formerly Miraculins Inc.) announces a corporate update which includes the plan for additional revenue streams in the diabetes sector, the amendment of its secured loans and the addition of Chief Executive Officer, Christian Sauvageau to the Board of Directors.The Company, through its newly formed subsidiary, MedPath Vitality Corp. ("MedPath Vitality®"),...
2016-06-22 9:00 AM EDT
Pharma Executive Christian Sauvageau Appointed New CEO of Luminor Medical Technologies
Winnipeg, Manitoba--(Newsfile Corp. - April 21, 2016) - Luminor Medical Technologies Inc. (TSXV: LMT) (the "Company" or "Luminor") (formerly Miraculins Inc.), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces the appointment of Christian Sauvageau as the Company's new President & CEO. Christopher J. Moreau has stepped down in his role as President & CEO of the Company, and as...
2016-04-21 7:00 AM EDT
Miraculins Announces Name Change, New Stock Symbol and Share Consolidation
Winnipeg, Manitoba--(Newsfile Corp. - April 13, 2016) - Miraculins Inc. (TSXV: MOM) (the "Company") announces that it has changed its name to Luminor Medical Technologies Inc. and will commence trading on the TSX Venture Exchange under the new symbol "LMT" at the open of market on April 14, 2016. As previously announced on March 22, 2016, the Company has also completed a twenty-five to one (25 - 1) consolidation of its common shares resulting in the Company having approximately...
2016-04-13 8:00 AM EDT
Miraculins Announces Proposed Share Consolidation and Results of Shareholders Meeting
Winnipeg, Manitoba--(Newsfile Corp. - March 23, 2016) - Miraculins Inc. (TSXV: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces that its Board of Directors ( the "Board") has approved a consolidation (the "Consolidation") of the Company's common shares ("Common Share" or "Common Shares") on the basis of twenty five pre-consolidation Common Shares...
2016-03-23 7:00 AM EDT
Miraculins Provides Update on Strategic Review Process
Winnipeg, Manitoba--(Newsfile Corp. - February 24, 2016) - Miraculins Inc. (TSXV: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today that pursuant to the strategic review process the Company has been undertaking, it will retain ownership of its Scout DS® lead technology. The Company also announces that it has made changes to its business plan and...
2016-02-24 8:30 AM EST
Miraculins Announces Secured Loan
Winnipeg, Manitoba--(Newsfile Corp. - February 17, 2016) - Miraculins Inc. (TSXV: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces that it has arranged a secured loan (the "Loan") totaling $100,000, with Bradstone Capital Corp. (the "Lender"), a company with an officer who is also an officer of the Company.The Loan shall mature the earlier of i)...
2016-02-17 8:16 AM EST
Miraculins Appoints Ashwath Mehra to the Board of Directors
Winnipeg, Manitoba--(Newsfile Corp. - February 9, 2016) - Miraculins Inc. (TSXV: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs announces today, the appointment of Mr. Ashwath Mehra to the Company's Board of Directors. Mr. Mehra holds a BSc (Econ) from the London School of Economics and is currently the CEO of the Astor Group, an investment and advisory group of...
2016-02-09 7:00 AM EST